Product lbl-019 injection of Leadsbiolabs has been approved by FDA for clinical trial!
Nanjing LeadsBiolabs Biotechnology Co , Ltd announced that its self-developed, global intellectual property TNFR2 monoclonal antibody LBL-019 clinical trial application has been approved by the US FDA for clinical trials